|
Peregrine Pharmaceuticals |
|
|
14282 Franklin Avenue
Tustin, CA 92780 USA
phone:714-508-6000
fax:714-838-5817
|
|
| Symbol |
PPHM |
| Exchange |
NASDAQ |
| Founded |
1981 |
| Employees |
133 |
|
|
| www.peregrineinc.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Peregrine is a biopharmaceutical company developing novel monoclonal antibody drugs for cancer and serious viral infections. |
|
| Management |
| Steven W. King, President and CEO, Director; Paul J. Lytle, CPA, Chief Financial Officer; Robert Garnick, Ph.D., Head of Regulatory Affairs; Marvin R. Garovoy, MD, Head of Clinical Science; Joseph Shan, M.P.H., Vice President, Clinical & Regulatory Affairs |
| |
|
|
|
|
|
|
|
| Keywords |
| oncology, pharmaceutical, peregrine, monoclonal, bavituximab |
|
|
|
| Description |
|
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. |
|
| Products / Services |
Peregrine has an extensive pipeline of platform technologies which are in various stages of pre-clinical and clinical development. The company?s current philosophy is to conduct basic research and early clinical development on technologies prior to licensing them to larger pharmaceutical companies for commercialization, although Peregrine may choose to develop and market its products for targeted or specialized uses on its own. Peregrine currently has numerous products in pre-clinical development and two products in clinical trials.
|
|
| Technology / Differentiation |
Phosphatidylserine (PS)-Targeting Technology Platform Bavituximab is the first in a new class of targeted anti-phosphatidylserine (PS) antibodies that targets and binds to the cellular membrane component PS.
Tumor Necrosis Therapy (TNT) Technology Platform
Peregrine's lead TNT technology product candidate |
|
| Market / Customers |
Peregrine's lead products bavituximab and Cotara are in mid-stage development for solid cancers, the second leading cause of death worldwide. In view of bavituximab's unique target, we expect that it could become part of the treatment regimen for many types of solid cancers. Cotara is intended for the glioblastoma market. A minimally effective chemotherapy drug currently approved for GBM generates U.S. sales of more than $500 million annually. Avid is a growing competitor in the fragmented but growing market for contract biomanufacturing services. Its sales have grown exponentially in recent years, with further growth expected from both biotechnology and pharmaceutical customers. Avid is also planning to apply its capabilities and expertise to the emerging market for biosimilar drugs.
|
|
| Competitors / Substitutes / Alternatives |
Other marketed cancer drugs and drugs in development, and other anti-viral therapies in development. Major unmet needs for improved therapies remain.
|
|
| Status |
Peregrine is committed to commercializing at least one product in the next 2.5-5 years. It plans to initiate a definitive bavituximab NSCLC Phase II clinical trial in early 2010 and is assessing options for accelerating the possible commercialization of Cotara for GBM.
Bavituximab is currently in three Phase II clinical trials for the treatment of solid cancers. Two trials are in patients with breast cancer and one is in patients with non-small cell lung cancer (NSCLC). Encouraging results have been reported from each of these trials, and patient follow-up is ongoing.
Bavituximab is also being tested in a Phase I clinical trial of HCV patients co-infected with HIV, and is being evaluated preclinically in a number of additional viral indications.
Cotara is being tested in a Phase II clinical trial in patients with recurrent GBM, and patient enrollment was recently completed in a dose confirmation and dosimetry trial of Cotara in patients with recurrent GBM. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
